Mesoblast Reports on Annual and Fourth Quarter Results
Filed with ASX · · 8 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallIn the deck
Story so far
Earlier from Mesoblast
- Update on Tasly transaction
- MSB Enters Into Cardiovascular Alliance For China With Tasly
- MSB Enters Into US$50M Financing With NovaQuest Capital
- Key Day 100 Survival Results In P3 GvHD Trial
- Partnership For Allogeneic Cell-based Cancer Immunotherapies
Later from Mesoblast
- Tasly Receives Approvals For Transaction With MSB
- Day 180 Survival Outcomes In aGvHD Phase 3 Trial
- Completion of Tasly Transaction, and Appendix 3B
- MSB Expands Partnership With JCR For Skin Disease
- LVAD Trial Results Provide Potential Regulatory Pathway
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast